Facet seeks better offer after Biogen Idec's bid falls through
This article was originally published in Scrip
Executive Summary
Facet Biotech is looking for companies to acquire it on better terms than the $17.50 per share offer by Biogen Idec that fell through this week. President and CEO Faheem Hasnain added that Facet continued "to offer Biogen Idec the opportunity to engage in due diligence discussions to determine whether [the latter] would make a materially increased offer".